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Background. The efficacy of alteplase in acute ischaemic stroke (AIS) is highly time dependent. Hence, alteplase is administered as
soon as possible with a bolus followed by an infusion. Delays between bolus and infusion may occur, but the extent of these delays
and the impact on outcome are unclear. Aims. We investigated the extent of bolus-infusion delays and the relationship between
delays and stroke outcome. Method. We reviewed medical records of 276 patients who received alteplase for AIS at our centre
between April, 2008, and June, 2013. Complete demographic and clinical data including 3-month modified Rankin Score (mRS)
from 229 patients were analysed comparing delays of 0–8 and >8 minutes. Results. Overall mean (SD) bolus-infusion delay was
9 (7) minutes. Baseline characteristics were similar apart from more severe strokes in delays >8 minutes. Three-month outcomes
were not significantly different although delays >8 minutes had lower functional independence rate (mRS 0-1: 23.1% versus 28.1%;
adjusted OR 1.2 (95% CI 0.6 to 2.4, 𝑃 = 0.68)) and higher mortality rate (18% versus 11%, OR 1.0, 95% CI 0.6 to 1.7, 𝑃 = 0.95).
Conclusions. In this single centre series, bolus-infusion delays of alteplase in AIS were common and no effect of bolus-infusion
delays on independence and mortality was found.
1. Introduction
Alteplase is licensed for use in acute ischaemic stroke (AIS).
Its efficacy in improving stroke outcome depends on onset
to treatment time (OTT) [1]. Alteplase has a short plasma
half-life of about 4 minutes [2] and is administered at a dose
of 0.9mg/kg body weight with 10% of the total dose given
as a bolus over 1-2 minutes and the remainder infused over
an hour. This regimen has been demonstrated to achieve
functional improvement with a low risk of intracranial
haemorrhage [3].
None of the trials of alteplase inAIS reported the extent of
bolus-infusion delays. Indeed, there are very limited data on
the pharmacokinetic profile of alteplase as used in AIS [4, 5].
Considering the short half-life of alteplase, significant bolus-
infusion delays may result in delayed or suboptimum steady
state kinetics which could adversely influence outcome.
We investigated the extent of bolus-infusion delays of
alteplase in AIS in a single centre and its relationship with
functional outcome at 3 months.
2. Materials and Methods
We retrospectively reviewed medical records of patients
treatedwith alteplasewithin 4.5 h afterAIS atNewcastle upon
Tyne Hospitals Trust from April 2008 to June 2013. Data
on baseline demographics and relevant clinical parameters,
functional outcome based on modified Rankin Scale (mRS)
score at 3 months, and time lapse between bolus and infusion
doses of alteplase were retrieved.
Bolus-infusion delays have been reported per typical half-
lives (4 minutes) and further categorized as 0–8 and >8
minutes for inference analysis based on the likelihood of
significant decline in plasma concentration of alteplase after
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a bolus-infusion delay of 2 half-lives [5]. Demographic and
clinical data have been reported as descriptive summaries
with inference statistics using independent 𝑡-test and chi-
square (𝜒2) test.
We analysed the relationship between independent func-
tional outcome (mRS 0-1 and 0–2) at 3 months and bolus-
infusion delays of 0–8 and >8 minutes using multivariable
logistic regression (MLR) adjusting for age, sex, blood pres-
sure, atrial fibrillation and hyperlipidaemia status, antiplatelet
use, prestroke mRS, Oxfordshire Community Stroke Project
classification, prethrombolysis NIHSS, and OTT. Patients
who received at least two-thirds of the total recommended
intravenous dose of alteplase without intra-arterial or
thrombectomy interventions were included in the analysis
based on pharmacokinetic models which predict attainment
of ≥90% of the potential peak plasma concentration from full
dose alteplase assuming a bolus injection time of 1minute and
bolus-infusion delay of 5–15 minutes [5]. IBM SPSS version
20 (New York, USA) and Stata statistical software version 12
(College Station, Texas, USA) were used for the analysis.
3. Results
Medical records of 276 patients with AIS treated with intra-
venous thrombolysis were reviewed. A total of 229 patients
were included in the analysis after the exclusion of 47
patients with incomplete data involving admission glucose,
infusion start time and/or mRS at 3 months (𝑛 = 24),
endovascular treatment including intra-arterial thrombolysis
and thrombectomy (𝑛 = 17), and administration of less
than two-thirds of total dose of alteplase mainly due to early
termination of alteplase infusion (𝑛 = 6). Demographic and
clinical characteristics of excluded patients were similar to
those included in the analysis.
Baseline characteristics were similar between the groups
with bolus-infusion delays of 0–8 and >8 minutes except for
the latter group that had more severe strokes as determined
by prethrombolysis NIHSS (Table 1). Bolus-infusion delays of
0–4, 5–8, 9–12, and >12 minutes occurred in 20%, 33%, 25%,
and 22% of patients, respectively, with an overall mean (SD)
delay of 9 (7) minutes.
Unadjusted functional independence at 3 months was
similar among the two groups (mRS 0–2: 50% versus 50%,
continuity correction 𝜒2 test = 0, unadjusted OR 1.0, 95% CI
0.6 to 1.7, and𝑃 = 0.95. mRS 0-1: 28.1% versus 23.1% for delays
of 0–8 and >8 minutes, resp., continuity correction 𝜒2 test =
0.495, unadjusted OR 0.8, 95% CI 0.4 to 1.4, and 𝑃 = 0.39).
Adjusted OR for an independent functional outcome for
delays >8 minutes was marginally significant at 2.1 (95% CI
1.0 to 4.1, 𝑃 = 0.04) based onmRS 0–2 but insignificant using
mRS 0-1 at 1.2 (95% CI 0.6 to 2.4, 𝑃 = 0.68). As expected,
independent functional outcome at 3 months was adversely
affected by higher prethrombolysis NIHSS score. Compared
withNIHSS 0–9, unadjustedOR for good functional outcome
were 0.28 (95% CI 0.14 to 0.56, 𝑃 < 0.001) and 0.07 (95%
CI 0.02 to 0.25, 𝑃 < 0.001) for NIHSS 10–19 and >19, and
adjusted ORwere 0.46 (95%CI 0.18 to 1.19,𝑃 = 0.11) and 0.10
(95% CI 0.02 to 0.42, 𝑃 = 0.002), respectively. The mortality
rate at 3monthswas nonsignificantly higher in the groupwith
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Figure 1: Bolus-infusion delays during treatment with intravenous
alteplase within 4.5 h and outcome at 3 months after stroke. mRS-
modified Rankin Scale.
delays >8 minutes (11% versus 18%, difference 7.8, CI −2.2
to 17.8, continuity correction 𝜒2 test = 2.2, and 𝑃 = 0.138)
(Figure 1).
4. Discussion
In this single centre study, we observed bolus-infusion delays
of >8 minutes in 47% of AIS patients treated with intra-
venous alteplase. Compared to those with delays >8 minutes,
bolus- infusion delays of ≤8 minutes were associated with
nonsignificantly higher independent functional outcome and
lower mortality rates after 3 months. Our findings are similar
to those reported in abstract form in a smaller series of
120 patients where no difference in functional outcome or
recanalisation was found [6].
In order to minimise OTT and optimise outcome, stroke
pathways have evolved to allow the administration of bolus
doses of alteplase as quickly as possible, sometimes in the
CT or MRI scanner. The infusion may then be started after
patients have been transferred to the acute stroke ward,
emergency department, or clinical treatment areas resulting
in delays between the administration of the bolus dose and
commencement of the infusion. We observed longer bolus-
infusion delays in patients with more severe strokes. This
might be due to a longer time taken to transfer the patients
from the CT table to the trolley which in our institution takes
place before the infusion is commenced.
In healthy cohort and myocardial infarction studies
using intravenous alteplase, the administration of a bolus
dose immediately before commencement of infusion led
to the attainment of steady state concentration in about
4 minutes [7] compared to about 20 minutes for infusion
only dosing [2]. With a mean bolus-infusion delay of 9
minutes (approximately 2 half-lives) in our cohort, peak
plasma concentrations after the administration of the bolus
dose of alteplase would have significantly dropped by about
75% at the time of initiation of the infusion. Moreover,
the infusion regimen delivers 1.5% of the total dose of
alteplase per minute compared to 10% for the bolus if given
over a minute. In cases of significant bolus-infusion delays,
therefore, the contribution of the bolus injection towards
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Table 1: Demographic and clinical characteristics of patients. Data presented as mean [SD] for continuous variables and proportions (%) for
categorical variables unless otherwise stated.
Characteristics Bolus-infusion delays
0–8 minutes
(𝑛 = 121)
>8 minutes
(𝑛 = 108)
Male sex 50 56
Mean age (years) 73 [11] 72 [12]
Mean weight (kg) 72 [14] 76 [16]
Mean systolic blood pressure (mmHg) 144 [22] 142 [22]
Mean diastolic blood pressure (mmHg) 78 [15] 76 [15]
Mean admission blood glucose (mmol/L) 7 [2] 7 [3]
Hypertension 71 59
Diabetes mellitus 13 12
Atrial fibrillation 37 45
Congestive cardiac failure 8 4
Hyperlipidaemia 45 45
TIA/amaurosis fugax 10 6
Previous stroke 14 12
Peripheral vascular disease 6 5
Myocardial infarction or ischaemic heart disease 19 30
Current smoker 15 18
Ex-smoker 26 22
Antiplatelet use 53 60
Pre-stroke mRS, median (IQR) 1 (0–2) 1 (0–2)
Mean onset to treatment time (OTT) in minutes; proportions within groups
0–90 79 [11]; 11% 74 [16]; 18%
91–180 132 [25]; 63% 132 [26]; 64%
181–270 212 [19]; 26% 209 [22]; 18%
0–270 147 [47] 136 [47]
Oxfordshire Community Stroke Project
Total anterior circulatory stroke 41 56
Partial anterior circulatory stroke 45 35
Lacunar stroke 12 6
Posterior circulatory stroke 2 4
Pre-thrombolysis neurological severity per NIHSS score
Median (IQR)∗ 10 [7–17] 14.5 [9–21]
Proportions within NIHSS categories (%)∗∗
0–9 49 30
10–19 35 37
>19 16 33
NIHSS—National Institutes of Health Stroke Scale; TIA—Transient Ischaemic Attack; mRS—modified Rankin Score. No significant differences between
infusion delays of 0–8 and >8 minutes except for ∗(Mann Whitney U test, 𝑃 = 0.016) and ∗∗(Pearson’s 𝜒2 test = 13.1, 𝑃 = 0.001).
steady state concentration could wane resulting in a delayed
or suboptimum steady state concentration with potential
knock-on effects on achieving optimum fibrinolysis. This is
illustrated by delays in reaching initial peak concentrations of
approximately 20 and 30minutes in studies simulating bolus-
infusion delays of 5 and 15 minutes, respectively [5].
Intuitively, a shorter bolus-infusion delay was postulated
to be associated with improved outcome based on the attain-
ment of near optimum plasma alteplase concentrations. The
largely neutral three-month outcome measures may reflect
the higher antiplatelet use and shorter mean OTT, which are
associated with better outcome [1, 3] in the group with delays
>8 minute albeit with a higher prethrombolysis median
NIHSS (Table 1). It is possible that the effect of alteplase on the
fibrinolytic system in AIS is not only defined by the optimum
steady state concentrations envisaged from the immediate
commencement of the infusion after the bolus. Other factors
such as the speed of delivery of alteplase to, and saturation
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of, the plasminogen catalytic sites within the thrombus as
evident in the effect of OTT on outcome after AIS, may also
influence this [1]. This is consistent with the rationale for the
departure from a complete reliance on infusions as employed
in earlier trials [8].
Our study has a number of limitations. The data were
retrospectively retrieved from a single centre with over 15-
year experience of administering alteplase for AIS and it is
possible that delays may vary in other centres.
5. Conclusions
Our study demonstrates that bolus-infusion delays are likely
to be common. Delays of >8 minutes were not associated
with significantly worse outcomes although the functional
independence rate was lower and death rate was higher in this
group. The series is however small to conclusively define the
association between bolus-infusion delays and outcomes, as
such larger prospective studies will be useful.
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